Redx adds U.S. office while Jounce shareholders eye CVR’s upside in merger
Combined company will prioritize U.K. company’s ROCK2 program as deal adds to Redx’s balance sheet
Through a planned merger with Jounce, U.K.-based Redx will become a NASDAQ-listed company as it prioritizes a clinical ROCK2 program and develops a pipeline of small molecules for cancer and fibrosis.
The deal announcement came a day after Jounce Therapeutics Inc. (NASDAQ:JNCE) said it would lay off 57% of its staff and restructure. The immunotherapy company had decided not to advance two clinical programs on its own; its shareholders will receive a contingent value right tied to their advancement...
BCIQ Target Profiles
Inducible T cell co-stimulator (ICOS)
Leukocyte immunoglobin-like receptor subfamily B member 4 (LILRB4) (CD85k) (ILT3)
Leukocyte immunoglobulin-like receptor B1 (LILRB1) (ILT2)
Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) (LIR2) (ILT4)
Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Rho-associated coiled-coil containing protein kinase 2 (ROCK2)